References
- El-NaggarAKChanJKGrandisJRTakataTSlootwegPJWHO Classification of Head and Neck Tumours4th edIARCLyon2017
- Surveillance, Epidemiology, and End Results (SEER) ProgramSEER*Stat Database: Incidence – SEER 9 Available from: https://seer.cancer.gov/Accessed April 23, 2017
- PfisterDGSpencerSBrizelDMHead and neck cancers, version 1 2015J Natl Compr Canc Netw201513784785526150579
- SwaikaAHammondWAJosephRWCurrent state of anti-PD-L1 and anti-PD-1 agents in cancer therapyMol Immunol2015672 Pt A41725749122
- HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
- PardollDMSpinning molecular immunology into successful immunotherapyNat Rev Immunol20022422723812001994
- FreemanGJLongAJIwaiYEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationJ Exp Med200019271027103411015443
- ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
- ZhangYHuangSGongDQinYShenQProgrammed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancerCell Mol Immunol20107538939520514052
- MuenstSSoysalSDGaoFObermannECOertliDGillandersWEThe presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancerBreast Cancer Res Treat2013139366767623756627
- WuCZhuYJiangJZhaoJZhangXGXuNImmunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochem20061081192416530813
- ShiFShiMZengZPD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patientsInt J Cancer2011128488789620473887
- HamanishiJMandaiMIwasakiMProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci U S A200710493360336517360651
- BaptistaMZSarianLODerchainSFPintoGAVassalloJPrognostic significance of PD-L1 and PD-L2 in breast cancerHum Pathol2016471788426541326
- RozaliENHatoSVRobinsonBWLakeRALesterhuisWJProgrammed death ligand 2 in cancer-induced immune suppressionClin Dev Immunol2012201265634022611421
- GardnerDJefferyLESansomDMUnderstanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockadeAm J Transplant20141491985199125098238
- JiRRChasalowSDWangLAn immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunol Immunother20126171019103122146893
- AminMBEdgeSGreeneFAJCC Cancer Staging Manual8th edNew YorkSpringer2017
- McCartyKSJrMillerLSCoxEBKonrathJMcCartyKSSrEstrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodiesArch Pathol Lab Med198510987167213893381
- GuzzoMDi PalmaSGrandiCMolinariRSalivary duct carcinoma: clinical characteristics and treatment strategiesHead Neck19971921261339059870
- DillonPMChakrabortySMoskalukCAJoshiPJThomasCYAdenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trialsHead Neck201638462062725487882
- HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
- FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
- IgarashiTTeramotoKIshidaMHanaokaJDaigoYScoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factorsESMO Open201614e00008327843633
- KatsuyaYHorinouchiHAsaoTExpression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapyLung Cancer20169941027565906
- OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
- ShinSJJeonYKKimPJClinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins statusAnn Surg Oncol2016232694702
- PatelSPKurzrockRPD-L1 expression as a predictive biomarker in cancer immunotherapyMol Cancer Ther201514484785625695955